ExxonMobil's 2025 year-end results underscore a reshaped corporate strategy, delivering record shareholder returns and production milestones in Guyana and the Permian, while advancing carbon capture and enterprise digitalization.
Hardman Johnston Global Advisors has sold its entire stake in Corteva Inc. (NYSE: CTVA) following management discussions about potentially splitting the company's Seeds and Crop Protection units. The move highlights growing investor unease over strategic direction, liability concerns, and the unclear path to value creation, casting a shadow over the agricultural giant's recent strong performance.
Initial unemployment filings in Missouri fell by nearly 25% last week, a significant improvement that contrasts with mixed results seen in other states across the nation.
Truist Financial taps debt markets with a multi-billion dollar issuance, aiming to strengthen its funding base while sustaining shareholder returns amidst a shifting interest rate landscape.
The Hartford Financial Services Group reported robust fourth-quarter and full-year 2025 results, driven by profitable underwriting growth, higher investment income, and disciplined capital management. CEO Chris Swift outlined a strategic shift towards an "AI-first" operational model while signaling confidence in sustained margins and growth across business and personal lines.
Novo Nordisk's newly launched oral GLP-1 drug, amycretin, has seen explosive initial demand in the U.S., potentially setting the stage for a significant financial turnaround and stock rally after a challenging previous year.
Well-intentioned financial guidance from previous generations often fails to account for today's economic realities. From home ownership to savings accounts, we examine the advice that hasn't aged well and what you should consider instead.
New CMS reimbursement rates are pressuring Medicare Advantage profits, sending shares of Humana and CVS Health lower. We analyze whether the sell-off presents a buying opportunity for dividend investors or signals deeper structural challenges.
RBC Capital reaffirms its Outperform rating on UnitedHealth Group, citing management's commitment to long-term earnings targets, even as a lower-than-expected Medicare Advantage rate proposal triggers a sharp sell-off in the health insurer's shares.
Bitcoin struggles to find a floor, trading near November lows as the nomination of Kevin Warsh for Fed Chair fails to spark a rally. Persistent outflows from US spot ETFs and a broader risk-off mood compound the pressure, raising fresh doubts about the cryptocurrency's 'digital gold' narrative.
As demand surges post-pandemic, Royal Caribbean Group is committing billions to new ships and destinations. CFO Naftali Holtz details the balancing act between ambitious growth, shareholder returns, and leveraging AI to enhance the passenger experience.
The U.S. Office of the Comptroller of the Currency has granted Nubank conditional approval to establish a national bank, a significant step that could see the digital banking leader offer federally regulated crypto custody alongside traditional banking products in the United States.
As gold breaches historic price levels, retirees face critical decisions on how to integrate the precious metal into their portfolios. We examine the trade-offs between physical bars, coins, and ETFs in a transformed market.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
In a market fixated on tech giants, savvy investors are looking to regional financial institutions for sustainable growth. We analyze two banks with strong momentum and one where caution may be warranted, against a backdrop of shifting interest rates and economic uncertainty.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Amidst a market rally driven by a handful of tech giants, certain volatile stocks present outsized risks. We examine three names where valuation concerns and sector headwinds warrant a cautious approach.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
Options strategist Rick Orford outlines a disciplined, top-down screening methodology to filter the market for optimal covered call candidates, emphasizing stock quality over mere premium yield.
